The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial.

Abstract

In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.

• Authors: Winfred Wang, Carlo Brugnara, Cathie Snyder, Lynn Wynn, Zora Rogers, Karen Kalinyak, Clark Brown, Asif Qureshi, Carolyn Bigelow, Lynne Neumayr, Kim Smith-Whitley, David H K Chui, Mardee Delahunty, Rob Woolson, Martin Steinberg, Marilyn Telen, Karen Kesler
• Journal: British journal of haematology (Br J Haematol) Vol. 152 Issue 6 Pg. 771-6 (Mar 2011) ISSN: 1365-2141 [Electronic] England
• PMID: 21275961 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
• Copyright: © 2011 Blackwell Publishing Ltd.

Chemical References

• Antisickling Agents
• Biomarkers
• Fetal Hemoglobin
• Magnesium
• Hydroxyurea

Topics

• Adolescent
• Adult
• Antisickling Agents (therapeutic use)
• Biomarkers (blood)
• Cell Adhesion (drug effects)
• Child
• Child, Preschool
• Double-Blind Method
• Erythrocyte Indices (drug effects)
• Erythrocytes (drug effects, physiology)
• Female
• Fetal Hemoglobin (metabolism)
• Hemoglobin SC Disease (blood, drug therapy)
• Humans
• Hydroxyurea (adverse effects, therapeutic use)
• Magnesium (adverse effects, therapeutic use)
• Male
• Middle Aged